[{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"282c5598-a3f1-4e10-8b03-9fef7b6d2b9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468426","created_at":"2021-01-18T17:05:39.851Z","updated_at":"2024-07-02T16:35:11.588Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","source_id_and_acronym":"NCT03468426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 05/03/2018","start_date":" 05/03/2018","primary_txt":" Primary completion: 08/06/2024","primary_completion_date":" 08/06/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-04-03"},{"id":"e0f1a0c3-fe9e-435b-955f-31f344df4f2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499352","created_at":"2021-01-18T21:33:17.500Z","updated_at":"2024-07-02T16:36:20.753Z","phase":"Phase 2","brief_title":"A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer","source_id_and_acronym":"NCT04499352","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 836880"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 10/19/2020","primary_completion_date":" 10/19/2020","study_txt":" Completion: 10/19/2020","study_completion_date":" 10/19/2020","last_update_posted":"2021-11-15"}]